	Application No.	10/594,170
INFORMATION DISCLOSURE	Filing Date	July 20, 2007
STATEMENT BY APPLICANT	First Named Inventor	Gen-Sheng Feng
STATEMENT BY ALL EIGANT	Art Unit	1614
(Multiple sheets used when necessary)	Examiner	Unknown
SHEET 1 OF 1	Attorney Docket No.	RURNHAM OLONP

	U.S. PATENT DOCUMENTS				
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	6,262,044	07-17-2001	Moller et al.	
		Tanta to well was			

	FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	2	WO 99/46268	09-16-1999	Novo Nordisk A/S		

	T		
Examiner Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ¹
	3	CARPENTER, L. et al. (1998) "Enhancing leptin response by preventing sh2-containing phosphatase 2 interaction with ob receptor" <i>PNAS USA</i> 95:6061-6066.	
	5	INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY from PCT priority application serial no. PCT/US05/10380, November 14, 2007.	
	4	ZHANG, E. et al. (2004) "Neuronal shp2 tyrosine phosphatase controls energy balance and metabolism" <i>PNAS USA</i> 101:16064-16069.	,,,,

4641628:vo 121107

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.